We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Molecular Test Identifies Brain Tumors from Cerebrospinal Fluid

By LabMedica International staff writers
Posted on 07 Sep 2023
Print article
Image: The Real-CSF test measures abnormal genetic material circulating in cerebrospinal fluid (Photo courtesy of Johns Hopkins)
Image: The Real-CSF test measures abnormal genetic material circulating in cerebrospinal fluid (Photo courtesy of Johns Hopkins)

Doctors generally use MRI scans and biopsies to check for brain tumors. But sometimes, it's hard to tell if a brain lesion is cancerous or not using these usual methods. Now, researchers have developed a molecular test to identify the presence of brain tumors by measuring unusual genetic material that is released by tumors and circulates in cerebrospinal fluid (CSF).

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) have developed Real-CSF (repetitive element aneuploidy sequencing in CSF), a novel test that assesses aneuploidy (chromosome copy number alterations found in cancers) in over 350,000 regions of the genome simultaneously. Using a companion bioinformatics algorithm and machine-learning process, the test can identify the presence of cancers and their molecular characteristics in just two milliliters of CSF.

When the researchers tested Real-CSF in the lab using 280 CSF samples from people, some with brain cancer and some without, it accurately identified 67% of the cancerous brain lesions and 96% of the noncancerous ones. This outperformed the usual cytology testing approach, which only found 23% of cancers in a group of 121 patients. If more studies and tests show that Real-CSF works well, it could help doctors decide if a brain lesion is cancerous or not. It could also help them see how brain tumors are responding to treatment. The researchers now aim to make the test even better by combining it with gene mutations linked to cancer or changes in DNA that are only found in cancer.

“The test is very simple to use, works even on a limited amount of CSF and is inexpensive relative to many of the other liquid biopsy approaches on the market,” said senior study author Chetan Bettegowda, M.D., Ph.D. “With those characteristics, we were quite pleased that we had such a robust performance.”

Related Links:
Johns Hopkins Medicine 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.